RMIT is bringing together experts across multiple research disciplines to tackle diabetes treatment.
Type 1 diabetes, which destroys insulin producing islet beta cells, affects over 120,000 Australians and is a disease of national priority.
Being able to create insulin-producing cells, rather than relying on the very limited supply from human donors, is the ‘holy grail’ of diabetes research.
However, cross-disciplinary research to find a solution has been limited.
The PRINT-Cell initiative team are developing and testing soft tissue (islet) scaffolds using additive manufacturing (3D printing), tissue engineering and nanobiotechnology tools.
Their focus is on assessing the feasibility of 3D-printing replacement islet cells and developing a research plan and funding application for intensified cross‑disciplinary research in this area.
This project is funded through RMIT’s ECP Activity Support Initative Fund.